Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXS-5505 + ASTX727 for transfusion-dependent lower-risk myelodysplastic syndrome
ACTRN12625000201471Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of amsulostat and inqovi in myelodysplastic syndrome (MDS) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Safety and tolerability of PXS-5505 with ASTX727, Transfusion independence and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
amsulostatinqovi
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12625000201471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000201471.